Day: May 13, 2025

Winning entries to earn a share of $15,000 in prizes RESTON, Va., May 13, 2025 (GLOBE NEWSWIRE) — K12, a Stride, Inc. portfolio brand, announces the launch of its 19th Annual Art Competition, opening for submissions on May 13, 2025. The contest is open to all kindergarten through 12th grade students nationwide and offers young artists the opportunity to compete for a share of $15,000 in prizes. Designed to celebrate creativity and student expression, the K12 Art Competition invites original submissions across a variety of visual art forms, including painting, drawing and photography. This year’s competition welcomes sculptures and collages for the first time, and finalists will have the chance to present their work live to the judges over Zoom — offering a new way to highlight physical artwork. Entries will be judged by individual...

MIAMI, May 13, 2025 (GLOBE NEWSWIRE) — SKYX (NASDAQ: SKYX) (d/b/a “SKYX Technologies”), a highly disruptive advanced and smart home platform technology company for homes and buildings, with more than 97 issued and pending patents globally and a portfolio of over 60 lighting and home décor websites, announced today that it has secured approximately $4 million in recent funding from strategic investors through the purchase of preferred stock representing $2.00 per share. This investment is part of a broader financing round totaling approximately $15 million to date, led by The Shaner Group, owner and developer of more than 70 hotels worldwide. The $15 million broader funding round also included substantial participation from company insiders, including SKYX President Steve Schmidt and Co-CEOs Lenny Sokolow and John Campi,...

Saint-Cyr-sur-Mer, France, May 13, 2025 (GLOBE NEWSWIRE) —SEALSQ Brings Together Global Experts to Accelerate Post-Quantum and Space Security InnovationsSaint-Cyr-sur-Mer, France – May 13, 2025 — SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced the successful conclusion of its French Quantum and Space Day, held May 12–13, 2025, at Hotel Le Fregate, near Marseille. The two-day event brought together over 200 global experts, industry leaders, and government representatives for an unprecedented exchange on quantum technologies, post-quantum cybersecurity, and space infrastructure resilience. Following the momentum of earlier editions in Davos and New...

Discussion in Virtual Investor CEO Connect focuses on Company’s planned follow-on market expansion study phase (“PoC 2”) of proof-of-concept trial; Access Here Additional indications potentially double the addressable market beyond pancreatic cancer pain Follow-on expansion phase expected to begin in Q2 2025 THE WOODLANDS, TX, May 13, 2025 (GLOBE NEWSWIRE) — – Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today reiterated its plans for a follow-on phase to its proof-of-concept human clinical trial (“PoC 2”) evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate cancer pain. Additionally,...

— AMD EPYC 4005 Processors provide a compelling balance of performance, dependability and efficiency in an affordable, easy-to-deploy platform — SANTA CLARA, Calif., May 13, 2025 (GLOBE NEWSWIRE) — AMD (NASDAQ: AMD) today announced the launch of AMD EPYC™ 4005 Series processors. These purpose-built processors enable right-sized solutions with enterprise-class features and leadership performance for small and medium businesses and hosted IT service providers. AMD EPYC 4005 Series CPUs deliver the performance, features and efficiency growing businesses need to power everything from enterprise applications and virtualized environments to dedicated, all-day hosted services in the cloud. Utilizing the same proven and widely deployed AM5 socket used for the AMD EPYC 4004 Series CPUs, the EPYC 4005 Series delivers an innovative...

– Expect to report topline data from the Seabreeze STAT Asthma study in 1H 2026 – – On track to initiate similarly-designed Phase 2 study in patients with COPD imminently – SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) — Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced the initiation of its Phase 2 Seabreeze STAT Asthma study (NCT06940141) following written agreement on the final study protocol from the U.S. Food and Drug Administration. The study will evaluate the safety and efficacy of rademikibart as an adjunct to standard of care for acute exacerbations in adults and adolescent participants with asthma and type 2 inflammation. “We...